Erasca (ERAS) vs Indivior Pharmaceuticals (INDV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Indivior Pharmaceuticals (INDV) over the past year, gaining 536.2% versus a gain of 47.3%. Over five years, INDV leads with a +123.7% price change compared with -13.1% for ERAS. Erasca is the larger company by market cap ($5.54 billion vs $4.26 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | INDV |
|---|---|---|
| Share price | $15.84 | $36.06 |
| Market cap | $5.54B | $4.26B |
| 1-day change | +2.46% | +1.72% |
| YTD return | +315.59% | -1.20% |
| 1-year return | +536.21% | +47.28% |
| 5-year return | -13.15% | +123.66% |
| P/E ratio (TTM) | — | 12.92 |
| Forward P/E | — | 7.38 |
| EPS (TTM) | $-0.95 | $2.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.24B |
| Revenue growth (YoY) | — | +4.29% |
| Net income (latest FY) | $-124.55M | $210.00M |
| Gross margin | — | 80.23% |
| Operating margin | — | 21.15% |
| Net margin | — | 16.95% |
| 52-week high | $24.28 | $42.81 |
| 52-week low | $2.11 | $22.95 |
| Distance from 52-week high | -34.76% | -15.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +52.21% | +35.88% |
| Average volume | 4.37M | 2.07M |
| Shares outstanding | 349.76M | 118.03M |
| Employees | 103 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed INDV by 488.9 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
ERAS vs INDV FAQ
Which is bigger, Erasca or Indivior Pharmaceuticals?
Erasca (ERAS) is larger, with a market capitalization of $5.54B compared with $4.26B for Indivior Pharmaceuticals (INDV).
Which stock has performed better over the past year, ERAS or INDV?
ERAS returned +536.21% over the past 12 months, compared with +47.28% for INDV (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Indivior Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.